How much funding has JUST Biotherapeutics raised?

JUST Biotherapeutics has raised $118.7M in total funding, most recently a Series B round.

When was JUST Biotherapeutics founded?

JUST Biotherapeutics was founded in 2016.

Where is JUST Biotherapeutics headquartered?

JUST Biotherapeutics is headquartered in Hangzhou, China.

What industry is JUST Biotherapeutics in?

JUST Biotherapeutics operates in Biotech.

JUST Biotherapeutics

Q: Who are JUST Biotherapeutics's investors?

JUST Biotherapeutics's investors include Bill & Melinda Gates Foundation, Taikang Life Insurance, ARCH Venture Partners, Lilly Asia Ventures.

Hangzhou, China · Founded 2016 · $118.7M raised

Biotech

Headquarters: Hangzhou
Founded: 2016
Business Model: B2B
Website: hjbbio.com

Total Funding: $118.7M
Last Round: $35.0M Series BJun 2018
Rounds: 4

About

Hangzhou Just Biotherapeutics (HJB) was founded in August 2016 by Dr. Jonathan Y. Zhao, a former Amgen executive, as the CDMO arm of what would become Transcenta Holding Limited. The company provided end-to-end contract development and manufacturing services for large-molecule biotherapeutics, offering cell line development, process development, analytical services, formulation, and cGMP drug substance and drug product manufacturing from a facility in Hangzhou, China. In January 2019, HJB merged with MabSpace Biosciences to form Transcenta Holding Ltd., which completed an IPO on the Hong Kong Stock Exchange in September 2021; the combined entity was later acquired by Evotec AG and rebranded as Just-Evotec Biologics.

Summary

JUST Biotherapeutics is a Biotech company based in Hangzhou, China, founded in 2016. It has raised $118.7M in total across 4 rounds, most recently a $35.0M Series B round in Jun 2018. Investors include Bill & Melinda Gates Foundation, Taikang Life Insurance and ARCH Venture Partners.